Statins are lipid-lowering drugs that have been evaluated as a potential treatment for COVID-19 due to their pleiotropic effects, including anti-inflammatory, immunomodulatory, antioxidant, antithrombotic, and endothelium-stabilizing properties. A recent meta-analysis pooling results from 25 cohort studies suggested that statins may improve prognosis and decrease mortality in patients with COVID-19 [1]. Nevertheless, it is well known that observational studies may be misleading to build an evidence-based clinical practice.
